Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Leblebicioglu H., Arends J. E. , Ozaras R. , Corti G., Santos L., Boesecke C., ...Daha Fazla

ANTIVIRAL RESEARCH, cilt.150, ss.9-14, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.